OBJECTIVE: To evaluate the expression of programmed cell death-ligand 1 (PD-L1) in anal cancer. PATIENTS AND METHODS: In a retrospective cohort analysis, subjects with squamous cell carcinoma of the anal canal were tested for PD-L1 expression, then followed for recurrence and survival. Crude recurrence rates (CRRs), crude mortality rates (CMRs), and crude event rates (CERs) were assessed for PD-L1-dependent differences using Poisson regression. All 3 types of crude rate were expressed as the number that occurred per hundred person-years (hPY) of follow-up. RESULTS: Samples from 41 subjects were evaluated for PD-L1 expression; 23 (56%) were positive. Subjects with PD-L1-expressing versus PD-L1-negative tumors respectively had CRRs of 30.8 versus 12.1 recurrences/hPY (P=0.082), CMRs of 16.7 versus 12.0 deaths/hPY (P=0.47), and CERs of 39.2 versus 16.9 events/hPY (P=0.069). CONCLUSIONS: PD-L1 positivity was associated with worse CRR and CER, and marginally worse CMR. The effect on progression-free and overall survival needs to be validated in a study with a larger sample size.
OBJECTIVE: To evaluate the expression of programmed cell death-ligand 1 (PD-L1) in anal cancer. PATIENTS AND METHODS: In a retrospective cohort analysis, subjects with squamous cell carcinoma of the anal canal were tested for PD-L1 expression, then followed for recurrence and survival. Crude recurrence rates (CRRs), crude mortality rates (CMRs), and crude event rates (CERs) were assessed for PD-L1-dependent differences using Poisson regression. All 3 types of crude rate were expressed as the number that occurred per hundred person-years (hPY) of follow-up. RESULTS: Samples from 41 subjects were evaluated for PD-L1 expression; 23 (56%) were positive. Subjects with PD-L1-expressing versus PD-L1-negative tumors respectively had CRRs of 30.8 versus 12.1 recurrences/hPY (P=0.082), CMRs of 16.7 versus 12.0 deaths/hPY (P=0.47), and CERs of 39.2 versus 16.9 events/hPY (P=0.069). CONCLUSIONS:PD-L1 positivity was associated with worse CRR and CER, and marginally worse CMR. The effect on progression-free and overall survival needs to be validated in a study with a larger sample size.
Authors: Grace Lee; Daniel W Kim; Vinayak Muralidhar; Devarati Mitra; Nora K Horick; Christine E Eyler; Theodore S Hong; Lorraine C Drapek; Jill N Allen; Lawrence S Blaszkowsky; Bruce Giantonio; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jennifer Y Wo Journal: Oncologist Date: 2020-09-12
Authors: Joanna Gotfrit; Rachel Goodwin; Timothy Asmis; Angela J Hyde; Thierry Alcindor; Francine Aubin; Scott Berry; Dominick Bossé; Colin Brown; Ronald Burkes; Margot Burnell; Bruce Colwell; Jessica Corbett; Jeff Craswell; Nathalie Daaboul; Mark Doherty; D A Barry Fleming; Luisa Galvis; Rakesh Goel; Mohammed Harb; Alwin Jeyakumar; Derek Jonker; Erin Kennedy; Michael Lock; Aamer Mahmud; Patrick H McCrea; Vimoj Nair; Rami Nassabein; Carolyn Nessim; Ravi Ramjeesingh; Muhammad Raza; Wissam Saliba; Satareh Samimi; Simron Singh; Stephanie Snow; Mustapha Tehfé; Michael Thirlwell; Mario Valdes; Stephen Welch; Michael Vickers Journal: Curr Oncol Date: 2021-05-26 Impact factor: 3.677
Authors: Bahir H Chamseddin; Eunice E Lee; Jiwoong Kim; Xiaowei Zhan; Rong Yang; Kathleen M Murphy; Cheryl Lewis; Gregory A Hosler; Suntrea T Hammer; Richard C Wang Journal: Oncotarget Date: 2019-10-15